ArticleRisk management and healthcare policy2023

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer in China.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.